antibody

Goat anti-Prostaglandin dehydrogenase 1 Antibody

MBS421451

0.1 mg

300 USD

polyclonal

goat

nonconjugated

western blot, immunohistochemistry, enzyme immunoassay

Antibody

Goat anti-Prostaglandin dehydrogenase 1 Antibody

Prostaglandin dehydrogenase 1

HPGD; Prostaglandin dehydrogenase 1; PGDH1; 15-PGDH; hydroxyprostaglandin dehydrogenase 15-(NAD); PGDH; SDR36C1; NAD+-dependent 15-hydroxyprostaglandin dehydrogenase; short chain dehydrogenase/reductase family 36C, member 1; Prostaglandin dehydrogenase 1 antibody; HPGD antibody; PGDH1 antibody; 15-PGDH antibody; hydroxyprostaglandin dehydrogenase 15-(NAD) antibody; Prostaglandin dehydrogenase 1; Prostaglandin dehydrogenase 1

15-hydroxyprostaglandin dehydrogenase; 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; 15-hydroxyprostaglandin dehydrogenase [NAD(+)]; hydroxyprostaglandin dehydrogenase 15-(NAD); Prostaglandin dehydrogenase 1; Short chain dehydrogenase/reductase family 36C member 1

HPGD

HPGD; HPGD; PGDH; PGDH1; PHOAR1; 15-PGDH; SDR36C1; PGDH1; SDR36C1; 15-PGDH

PGDH_HUMAN

Polyclonal

Goat

Tested: Human; Expected from sequence similarity: Human

266

DYDTTPFQAKTQ

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul

Aliquot and store at -20 degree C. Minimize freezing and thawing.

Peptide ELISA (EIA), Western Blot (WB), Immunohistochemistry (IHC)

Peptide ELISA: Antibody detection limit dilution 1: 128000. Immunohistochemistry: In paraffin embedded Human Colon shows strong cytoplasm staining of enterocytes. Recommended concentration, 2-4ug/ml. Western Blot: Experiments gave bands at approx 26kDa and 50kDa in Human Duodenum lysates after 0.1ug/ml antibody staining. These bands correspond to earlier findings in literature with different antibodies (PMID: 11889207). This protein has a calculated MW of 29. 0kDa according to NP_000851. Recommended concentration: 0.1-1ug/ml.

Immunogen: Peptide with sequence C-DYDTTPFQAKTQ, from the C Terminus of the protein sequence according to NP_000851.2. Epitope: C Terminus

31542939

NP_000851.2

NM_000860.5

21,526 Da

Arachidonic Acid Metabolism Pathway (1270087); Metabolism Pathway (1269956); Metabolism Of Lipids And Lipoproteins Pathway (1270001); Prostaglandin Synthesis And Regulation Pathway (198912); Synthesis Of Lipoxins (LX) Pathway (1270093); Synthesis Of Prostaglandins (PG) And Thromboxanes (TX) Pathway (1270088); Transcriptional Misregulation In Cancer Pathway (523016); Transcriptional Misregulation In Cancer Pathway (522987)

This gene encodes a member of the short-chain nonmetalloenzyme alcohol dehydrogenase protein family. The encoded enzyme is responsible for the metabolism of prostaglandins, which function in a variety of physiologic and cellular processes such as inflammation. Mutations in this gene result in primary autosomal recessive hypertrophic osteoarthropathy and cranioosteoarthropathy. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2009]

HPGD: Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. Defects in HPGD are the cause of hypertrophic osteoarthropathy, primary, autosomal recessive, type 1 (PHOAR1). A disease characterized by digital clubbing, periostosis, acroosteolysis, painful joint enlargement, and variable features of pachydermia that include thickened facial skin and a thickened scalp. Other developmental anomalies include delayed closure of the cranial sutures and congenital heart disease. Defects in HPGD are the cause of cranioosteoarthropathy (COA). A form of osterarthropathy characterized by swelling of the joints, digital clubbing, hyperhidrosis, delayed closure of the fontanels, periostosis, and variable patent ductus arteriosus. Pachydermia is not a prominent feature. Defects in HPGD are a cause of isolated congenital nail clubbing (ICNC); also called clubbing of digits or hereditary acropachy. ICNC is a rare genodermatosis characterized by enlargement of the nail plate and terminal segments of the fingers and toes, resulting from proliferation of the connective tissues between the nail matrix and the distal phalanx. It is usually symmetrical and bilateral (in some cases unilateral). In nail clubbing usually the distal end of the nail matrix is relatively high compared to the proximal end, while the nail plate is complete but its dimensions and diameter more or less vary in comparison to normal. There may be different fingers and toes involved to varying degrees. Some fingers or toes are spared, but the thumbs are almost always involved. Belongs to the short-chain dehydrogenases/reductases (SDR) family. 2 isoforms of the human protein are produced by alternative splicing. Protein type: Oxidoreductase; Tumor suppressor; EC 1.1.1.141. Chromosomal Location of Human Ortholog: 4q34-q35. Cellular Component: basolateral plasma membrane; cytoplasm; cytosol; nucleoplasm. Molecular Function: 15-hydroxyprostaglandin dehydrogenase (NAD+) activity; catalytic activity; NAD binding; prostaglandin E receptor activity; protein homodimerization activity. Biological Process: female pregnancy; lipoxygenase pathway; negative regulation of cell cycle; ovulation; parturition; prostaglandin metabolic process; transforming growth factor beta receptor signaling pathway. Disease: Digital Clubbing, Isolated Congenital; Hypertrophic Osteoarthropathy, Primary, Autosomal Recessive, 1

0.1 mg

300 USD